CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

Michael Peter Diamond, V Limmroth, F Barkhof, N Desem, G Tachas

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS).

METHODS: In a multicenter, double-blind, placebo-controlled randomized phase II trial, 77 patients with RRMS were treated with 200 mg of ATL1102 subcutaneously injected 3 times in the first week and twice weekly for 7 weeks or placebo and monitored for a further 8 weeks. MRI scans were taken at baseline and weeks 4, 8, 12, and 16. The primary endpoint was the cumulative number of new active lesions (either new gadolinium-enhancing T1 lesions or nonenhancing new or enlarging T2 lesions) at weeks 4, 8, and 12.

RESULTS: A total of 72 patients completed the study and 74 intention-to-treat patients were assessed. ATL1102 significantly reduced the cumulative number of new active lesions by 54.4% compared to placebo (mean 3.0 [SD 6.12] vs 6.2 [9.89], p = 0.01). The cumulative number of new gadolinium-enhancing T1 lesions was reduced by 67.9% compared to placebo (p = 0.002). Treatment-emergent adverse events included mild to moderate injection site erythema and decrease in platelet counts that returned to within the normal range after dosing.

CONCLUSIONS: In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders.

CLASSIFICATION: This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions.

Original languageEnglish (US)
Pages (from-to)1780-8
Number of pages9
JournalNeurology
Volume83
Issue number20
DOIs
StatePublished - Nov 11 2014

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Antisense Oligonucleotides
Placebos
Pharmaceutical Preparations
Gadolinium
Integrin alpha4beta1
Erythema
Platelet Count
Reference Values
Therapeutics
Head
Magnetic Resonance Imaging
RNA
Safety
Injections

Keywords

  • Adolescent
  • Adult
  • Disability Evaluation
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Integrin alpha4
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting
  • Oligodeoxyribonucleotides, Antisense
  • Time Factors
  • Treatment Outcome
  • Young Adult
  • Clinical Trial, Phase II
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Cite this

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. / Diamond, Michael Peter; Limmroth, V; Barkhof, F; Desem, N; Tachas, G.

In: Neurology, Vol. 83, No. 20, 11.11.2014, p. 1780-8.

Research output: Contribution to journalArticle

Diamond, Michael Peter ; Limmroth, V ; Barkhof, F ; Desem, N ; Tachas, G. / CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. In: Neurology. 2014 ; Vol. 83, No. 20. pp. 1780-8.
@article{d313b7bc12bb46d38f3a011087dbf2e5,
title = "CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS",
abstract = "OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS).METHODS: In a multicenter, double-blind, placebo-controlled randomized phase II trial, 77 patients with RRMS were treated with 200 mg of ATL1102 subcutaneously injected 3 times in the first week and twice weekly for 7 weeks or placebo and monitored for a further 8 weeks. MRI scans were taken at baseline and weeks 4, 8, 12, and 16. The primary endpoint was the cumulative number of new active lesions (either new gadolinium-enhancing T1 lesions or nonenhancing new or enlarging T2 lesions) at weeks 4, 8, and 12.RESULTS: A total of 72 patients completed the study and 74 intention-to-treat patients were assessed. ATL1102 significantly reduced the cumulative number of new active lesions by 54.4{\%} compared to placebo (mean 3.0 [SD 6.12] vs 6.2 [9.89], p = 0.01). The cumulative number of new gadolinium-enhancing T1 lesions was reduced by 67.9{\%} compared to placebo (p = 0.002). Treatment-emergent adverse events included mild to moderate injection site erythema and decrease in platelet counts that returned to within the normal range after dosing.CONCLUSIONS: In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders.CLASSIFICATION: This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions.",
keywords = "Adolescent, Adult, Disability Evaluation, Double-Blind Method, Female, Follow-Up Studies, Humans, Integrin alpha4, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Oligodeoxyribonucleotides, Antisense, Time Factors, Treatment Outcome, Young Adult, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "Diamond, {Michael Peter} and V Limmroth and F Barkhof and N Desem and G Tachas",
note = "{\circledC} 2014 American Academy of Neurology.",
year = "2014",
month = "11",
day = "11",
doi = "10.1212/WNL.0000000000000926",
language = "English (US)",
volume = "83",
pages = "1780--8",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",

}

TY - JOUR

T1 - CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

AU - Diamond, Michael Peter

AU - Limmroth, V

AU - Barkhof, F

AU - Desem, N

AU - Tachas, G

N1 - © 2014 American Academy of Neurology.

PY - 2014/11/11

Y1 - 2014/11/11

N2 - OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS).METHODS: In a multicenter, double-blind, placebo-controlled randomized phase II trial, 77 patients with RRMS were treated with 200 mg of ATL1102 subcutaneously injected 3 times in the first week and twice weekly for 7 weeks or placebo and monitored for a further 8 weeks. MRI scans were taken at baseline and weeks 4, 8, 12, and 16. The primary endpoint was the cumulative number of new active lesions (either new gadolinium-enhancing T1 lesions or nonenhancing new or enlarging T2 lesions) at weeks 4, 8, and 12.RESULTS: A total of 72 patients completed the study and 74 intention-to-treat patients were assessed. ATL1102 significantly reduced the cumulative number of new active lesions by 54.4% compared to placebo (mean 3.0 [SD 6.12] vs 6.2 [9.89], p = 0.01). The cumulative number of new gadolinium-enhancing T1 lesions was reduced by 67.9% compared to placebo (p = 0.002). Treatment-emergent adverse events included mild to moderate injection site erythema and decrease in platelet counts that returned to within the normal range after dosing.CONCLUSIONS: In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders.CLASSIFICATION: This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions.

AB - OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS).METHODS: In a multicenter, double-blind, placebo-controlled randomized phase II trial, 77 patients with RRMS were treated with 200 mg of ATL1102 subcutaneously injected 3 times in the first week and twice weekly for 7 weeks or placebo and monitored for a further 8 weeks. MRI scans were taken at baseline and weeks 4, 8, 12, and 16. The primary endpoint was the cumulative number of new active lesions (either new gadolinium-enhancing T1 lesions or nonenhancing new or enlarging T2 lesions) at weeks 4, 8, and 12.RESULTS: A total of 72 patients completed the study and 74 intention-to-treat patients were assessed. ATL1102 significantly reduced the cumulative number of new active lesions by 54.4% compared to placebo (mean 3.0 [SD 6.12] vs 6.2 [9.89], p = 0.01). The cumulative number of new gadolinium-enhancing T1 lesions was reduced by 67.9% compared to placebo (p = 0.002). Treatment-emergent adverse events included mild to moderate injection site erythema and decrease in platelet counts that returned to within the normal range after dosing.CONCLUSIONS: In patients with RRMS, ATL1102 significantly reduced disease activity after 8 weeks of treatment and was generally well-tolerated. This trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders.CLASSIFICATION: This study provides Class I evidence that for patients with RRMS, the antisense oligonucleotide ATL1102 reduces the number of new active head MRI lesions.

KW - Adolescent

KW - Adult

KW - Disability Evaluation

KW - Double-Blind Method

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Integrin alpha4

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Oligodeoxyribonucleotides, Antisense

KW - Time Factors

KW - Treatment Outcome

KW - Young Adult

KW - Clinical Trial, Phase II

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1212/WNL.0000000000000926

DO - 10.1212/WNL.0000000000000926

M3 - Article

C2 - 25239835

VL - 83

SP - 1780

EP - 1788

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 20

ER -